Kliničke studije za Gliom u državi Texas
26 studija za Gliom traži sudionike na lokacijama u državi Texas.
Gradovi u državi Texas
Službeni tekst studije (engleski)
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- i još 8
U tijeku regrutacijaFaza 1/2
12 Months – 21 Years · Oba spola · Ažurirano 1. lis 2026. · NCT05099003A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
- Baylor College of Medicine, Houston
U tijeku regrutacijaFaza 1/2
Do 25 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT04094610MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT03896568ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Texas Children's Hospital, Houston
U tijeku regrutacijaFaza 2
12 Months – 39 Years · Oba spola · Ažurirano 21. ruj 2026. · NCT06838676MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
- M D Anderson Cancer Center, Houston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT04373720Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT04771806Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
- The University of Texas M. D. Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
36 Months · Oba spola · Ažurirano 9. ruj 2026. · NCT07076498Targeted Pediatric High-Grade Glioma Therapy
- Texas Children's Hospital, Houston
U tijeku regrutacijaOpažajna studija
12 Months – 39 Years · Oba spola · Ažurirano 8. ruj 2026. · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
36 Months – 22 Years · Oba spola · Ažurirano 4. ruj 2026. · NCT03911388Study of Olutasidenib and Temozolomide in HGG
- Texas Children's Hospital, Houston
U tijeku regrutacijaFaza 2
Od 12 do 39 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- University of Texas Health Mays Cancer Center, San Antonio
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT05303519PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Texas Children's Hospital, Houston
U tijeku regrutacijaFaza 2
Od 3 do 39 godina · Oba spola · Ažurirano 24. kol 2026. · NCT05096481Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 21. kol 2026. · NCT01772771Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- University Of Texas Southwestern Medical Center, Dallas
U tijeku regrutacijaFaza 1
Od 1 do 25 godina · Oba spola · Ažurirano 18. kol 2026. · NCT04485559Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Houston
- Research Site, San Antonio
U tijeku regrutacijaFaza 1/2
Od 18 do 130 godina · Oba spola · Ažurirano 12. kol 2026. · NCT05417594Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
- Excel Diagnostics & Nuclear Oncology Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 7. kol 2026. · NCT07733674C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
- Texas Children's Hospital, Houston
U tijeku regrutacijaFaza 1
12 Months – 25 Years · Oba spola · Ažurirano 3. kol 2026. · NCT04099797A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
U tijeku regrutacijaFaza 2
Od 8 godina i više · Oba spola · Ažurirano 27. srp 2026. · NCT05503797Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Texas Children's Hospital, Houston
U tijeku regrutacijaRana faza 1Zdravi dobrovoljci dobrodošli
Od 1 do 21 godina · Oba spola · Ažurirano 29. lip 2026. · NCT06333899Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaRana faza 1
Od 18 godina i više · Oba spola · Ažurirano 12. lip 2026. · NCT05804227Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Texas Children's Hospital, Houston
U tijeku regrutacijaFaza 2
12 Months – 39 Years · Oba spola · Ažurirano 29. svi 2026. · NCT05843253A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. tra 2026. · NCT06326411Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 13. tra 2026. · NCT06810544A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Texas Children's Hospital, Houston
U tijeku regrutacijaRana faza 1
Do 21 godina · Oba spola · Ažurirano 18. ožu 2026. · NCT04655404Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
- The Cancer Therapy and Research Center at UTHSCSA, San Antonio
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 30. ožu 2025. · NCT05460507Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- UT Southwestern Medical Center, Dallas
- The Cancer Therapy and Research Center at UTHSCSA, San Antonio
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 26. ožu 2025. · NCT01906385Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.